PYPD is expected to report earnings to fall 6.56% to -113 cents per share on February 05
Q4'24
Est.
$-1.14
Q3'24
Missed
by $0.22
Q2'24
Beat
by $0.05
Q1'24
Beat
by $2.78
Q4'23
Missed
by $0.39
The last earnings report on November 13 showed earnings per share of -122 cents, missing the estimate of -100 cents. With 19.09K shares outstanding, the current market capitalization sits at 19.54M.
a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes